Celltrion's Zymfentra gets 90% distribution channel in US

Its subcutaneous injection formulation for autoimmune diseases entered all six public and private insurance plans in PBM

Celltrion's Zymfentra gets 90% distribution channel in US
Dae-Kyu Ahn 1
2024-10-30 12:08:13 powerzanic@hankyung.com
Bio & Pharma

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), got 90% of the distribution channel in the US. 

The company said on Tuesday that it succeeded in listing Zymfentra in all six public and private insurance programs managed by the three largest US pharmacy benefit managers (PBMs).

The PBMs act as intermediaries between pharmacies, drug manufacturers, and insurance companies.

Celltrion’s coverage across all three PBMs marks a significant milestone for the South Korean pharmaceutical industry. It follows SK Biopharm’s epilepsy drug Xcopri, which succeeded in 2021.

Zymfentra, a self-administered version of Celltrion's intravenous biosimilar Remsima, was approved as a new drug in the US last October.

Celltrion forecasts Zymfentra sales to reach 250 billion won ($189 million) this year and expects this to grow to 1 trillion won in 2025 and 2 trillion won in 2026.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Zymfentra #listing Zymfentra US PBM

Celltrion's Zymfentra joins US insurance-covered drug lists

Celltrion's Zymfentra joins US insurance-covered drug lists

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), has joined the insurance-covered drug lists by three major US Prescription Benefit Managers (PBMs) after its US launch in March.The three PBM

Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

Celltrion Group founder and Chairman Seo Jung-jin (on left) visiting the Celltrion booth at DDW 2024  WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after a well-known pharmaceutical company in

Celltrion'a autoimmune disease drug Zymfentra makes US debut

Celltrion'a autoimmune disease drug Zymfentra makes US debut

Celltrion headquarters in Incheon, South Korea South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US market. The drug is a subcutaneous injection of Celltrion’s infliximab Remsima, a treatment for
(* comment hide *}